BTS Research Successfully Completes USDA Inspection with Zero Findings

BTS Research Successfully Completes USDA Inspection with Zero Findings San Diego, CA — August 28, 2024 — BTS Research, a leading contract research organization specializing in preclinical research services, is proud to announce the successful completion of its USDA inspection with zero findings. The inspection was triggered by the recent acquisition of BTS Research by…

Read More

PharmaLegacy acquires preclinical CRO BTS Research,

PharmaLegacy acquires preclinical CRO BTS Research PharmaLegacy acquires preclinical CRO BTS Research, strengthening its preclinical services and expanding laboratory operations into North America PharmaLegacy Laboratories, a provider of in vitro and in vivo preclinical drug development services, has acquired BTS Research, a San Diego-based preclinical contract research organization (CRO). As a reputable CRO providing preclinical…

Read More

BTS Research Addresses FDA Warning Letter Satisfactorily

BTS Research Addresses FDA Warning Letter Satisfactorily From the desk of the President & CEO, April 1st, 2024 BTS is very pleased to have received a satisfactory completion of the findings the FDA had issued a warning letter on October 20th 2023. The findings were originally noted during their June 27th 2022 audit, which centered around…

Read More

BTS Research Completes Corrections of FDA 483 Observations

BTS Research Completes Corrections of FDA 483 Observations From the desk of the President & CEO On July 8, 2022, U.S. Food and Drug Administration (FDA) Investigator concluded an inspection of the BTS Research facilities located in San Diego, CA and issued Inspectional Observations on the form FDA-483 that triggered a Warning Letter issued on…

Read More